top | item 27776410 Pharma Biogen,FDA walk back controversial Aduhelm label after fierce criticism 6 points| jk888 | 4 years ago |fiercepharma.com 1 comment order hn newest s1artibartfast|4 years ago This is why Medicare needs to adopt a quality adjusted life year test for medical reimbursement, like most countries with socialized healthcare.The FDA should not be taking costs and pricing into account when approving new drugs.Similarly, the taxpayers should not be on the hook for speculative new treatments.
s1artibartfast|4 years ago This is why Medicare needs to adopt a quality adjusted life year test for medical reimbursement, like most countries with socialized healthcare.The FDA should not be taking costs and pricing into account when approving new drugs.Similarly, the taxpayers should not be on the hook for speculative new treatments.
s1artibartfast|4 years ago
The FDA should not be taking costs and pricing into account when approving new drugs.
Similarly, the taxpayers should not be on the hook for speculative new treatments.